Medivir's BioPhausia subsidiary sells generic business to Bluefish
This article was originally published in Scrip
Executive Summary
Following on from Medivir’s acquisition of fellow Swedish firm, BioPhausia, comes the announcement that BioPhausia’s generic business is to be sold to Stockholm-based generics specialist, Bluefish Pharmaceuticals, for SEK26 million (€2.9 million; $4.1 million) plus the value of inventories, some SEK 12 million (€1.3 million; $1.9 million).